{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:45:46Z","timestamp":1781801146340,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T00:00:00Z","timestamp":1527552000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key R&D Program of China","award":["SQ2017YFSF080001"],"award-info":[{"award-number":["SQ2017YFSF080001"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81501236"],"award-info":[{"award-number":["81501236"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13048-018-0418-8","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T09:35:30Z","timestamp":1527586530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical analysis of chemo-resistance risk factors in endometriosis associated ovarian cancer"],"prefix":"10.1186","volume":"11","author":[{"given":"Tong","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Ting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-He","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,29]]},"reference":[{"key":"418_CR1","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ygyno.2008.02.006","volume":"109","author":"JK Chan","year":"2008","unstructured":"Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 2008;109:370\u20136.","journal-title":"Gynecol Oncol"},{"key":"418_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1006\/gyno.1998.5071","volume":"70","author":"K Behbakht","year":"1998","unstructured":"Behbakht K, Randall TC, Benjamin I, Morgan AM, King S, Rubin CS. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol. 1998;70:255\u20138.","journal-title":"Gynecol Oncol"},{"key":"418_CR3","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","volume":"88","author":"T Sugiyama","year":"2000","unstructured":"Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, et al. Clinical characteristics of clear cell carcinoma of the ovary. A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584\u20139.","journal-title":"Cancer"},{"issue":"2","key":"418_CR4","first-page":"281","volume":"100","author":"H Itamochi","year":"2002","unstructured":"Itamochi H, Kigawa J, Sugiyama T, et al. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary[J]. Obstet Gynecol. 2002;100(2):281\u20137.","journal-title":"Obstet Gynecol"},{"key":"418_CR5","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/IGC.0b013e3181dd0110","volume":"20","author":"HJ Mackay","year":"2010","unstructured":"Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart AM, et al. Gynecologic Cancer InterGroup. Prognostic relevance of uncommon ovarian histology in women with stage III\/IV epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20:945\u201352.","journal-title":"Int J Gynecol Cancer"},{"key":"418_CR6","doi-asserted-by":"crossref","unstructured":"FC1 K, RC2 W, LY3 Y, et al. Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: Results from a single-center Taiwanese study. J Formos Med Assoc. 2018;117:117\u201325.","DOI":"10.1016\/j.jfma.2017.03.007"},{"issue":"1","key":"418_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3802\/jgo.2013.24.1.37","volume":"24","author":"M Miyamoto","year":"2013","unstructured":"Miyamoto M, Takano M, Goto T, et al. Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review [J]. J Gynecol Oncol. 2013;24(1):37\u201343.","journal-title":"J Gynecol Oncol"},{"key":"418_CR8","first-page":"1797","volume":"22","author":"TKC Enomoto","year":"2003","unstructured":"Enomoto TKC, Yamasaki M, Kuragaki M, Sagita Y, Otsuki H, Ikegami N, et al. Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol. 2003;22:1797.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"418_CR9","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ygyno.2012.02.016","volume":"125","author":"AJ Rauh-Hain","year":"2012","unstructured":"Rauh-Hain AJ, Winograd D, Growdon WB, Schorge JO, Goodman AK, Boruta DM, et al. Prognostic determinants in patients with uterine and ovarian clear cell carcinoma. Gynecol Oncol. 2012;125:376\u201380.","journal-title":"Gynecol Oncol"},{"issue":"29","key":"418_CR10","first-page":"2030","volume":"91","author":"XD Liang","year":"2011","unstructured":"Liang XD, Zeng HX, Zhu HL, Feng YY, Yin LY, Cui H, Wei LH. Prediction of chemoresistance in epithelial ovarian cancer by clinical factors. Zhonghua Yi Xue Za Zhi. 2011;91(29):2030\u20133.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"418_CR11","doi-asserted-by":"publisher","first-page":"349Y353","DOI":"10.1159\/000065067","volume":"62","author":"H Itamochi","year":"2002","unstructured":"Itamochi H, Kigawa J, Akeshima R, et al. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary. Oncology. 2002;62:349Y353.","journal-title":"Oncology"},{"key":"418_CR12","doi-asserted-by":"publisher","first-page":"653Y658","DOI":"10.1111\/j.1349-7006.2008.00747.x","volume":"99","author":"H Itamochi","year":"2008","unstructured":"Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci. 2008;99:653Y658.","journal-title":"Cancer Sci"},{"key":"418_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/excr.1998.4299","volume":"246","author":"N Claij","year":"1999","unstructured":"Claij N, te Riele H. Microsatellite instability in human cancer: a prognostic marker for chemotherapy? Exp Cell Res. 1999;246:1\u201310.","journal-title":"Exp Cell Res"},{"key":"418_CR14","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.humpath.2003.12.009","volume":"35","author":"KQ Cai","year":"2004","unstructured":"Cai KQ, Albarracin C, Rosen D, et al. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol. 2004;35:552\u20139.","journal-title":"Hum Pathol"},{"issue":"5","key":"418_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/cas.12390","volume":"105","author":"K Niimi","year":"2014","unstructured":"Niimi K, Murakumo Y, Watanabe N, et al. Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells. Cancer Sci. 2014;105(5):545\u201352.","journal-title":"Cancer Sci"},{"issue":"1","key":"418_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/IGC.0000000000000014","volume":"24","author":"H Itamochi","year":"2014","unstructured":"Itamochi H, Nishimura M, Oumi N, et al. Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer. 2014;24(1):61\u20139.","journal-title":"Int J Gynecol Cancer"},{"key":"418_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0092-8674(02)00625-6","volume":"108","author":"RW Johnstone","year":"2002","unstructured":"Johnstone RW, Ruefli AA, Lowe SW. Apoptosis. a link between cancer genetics and chemotherapy. Cell. 2002;108:153\u201364.","journal-title":"Cell"},{"key":"418_CR18","first-page":"2448","volume":"8","author":"M Fujimura","year":"2002","unstructured":"Fujimura M, Hidaka T, Saito S. Selective inhibition of the epidermal growth factor receptor by ZD1839 decreases the growth and invasion of ovarian clear cell adenocarcinoma cells. Clin Cancer Res. 2002;8:2448\u201354.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"418_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10456-010-9199-4","volume":"14","author":"GK Siddiqui","year":"2011","unstructured":"Siddiqui GK, Maclean AB, Elmasry K, et al. Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer. Angiogenesis. 2011;14(2):155\u201361.","journal-title":"Angiogenesis"},{"issue":"8","key":"418_CR20","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1158\/1535-7163.MCT-10-0169","volume":"9","author":"S Mabuchi","year":"2010","unstructured":"Mabuchi S, Kawase C, Altomare DA, et al. Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther. 2010;9(8):2411\u201322.","journal-title":"Mol Cancer Ther"},{"key":"418_CR21","first-page":"4093","volume":"48","author":"EK Rowinsky","year":"1988","unstructured":"Rowinsky EK, Donehower RC, Jones RJ, Tucker RW. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res. 1988;48:4093\u2013100.","journal-title":"Cancer Res"},{"key":"418_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/00004347-199904000-00007","volume":"18","author":"CD Rolitsky","year":"1999","unstructured":"Rolitsky CD, Theil KS, McGaughy VR, Copeland LJ, Niemann TH. HER-2\/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol. 1999;18:138\u201343.","journal-title":"Int J Gynecol Pathol"},{"key":"418_CR23","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1186\/s12885-015-1504-6","volume":"15","author":"P-E M","year":"2015","unstructured":"M P-E, P K, U P. Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioid-type epithelial ovarian cancer. BMC Cancer. 2015;15:493.","journal-title":"BMC Cancer"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-018-0418-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-018-0418-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-018-0418-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T19:18:26Z","timestamp":1559071106000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-018-0418-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,29]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["418"],"URL":"https:\/\/doi.org\/10.1186\/s13048-018-0418-8","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,29]]},"assertion":[{"value":"12 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Obstetrics and Gynecology Peking Union Medical College Hospital Human Research Ethics Committee Approval was obtained for the use of all samples.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"40"}}